The impact of cyclosporine dose and level on acute rejection and patient and graft survival in liver transplant recipients

R. H. Wiesner, R. M. Goldstein, J. P. Donovan, C. M. Miller, J. R. Lake, M. R. Lucey

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A multicenter, retrospective analysis of 623 liver transplant recipients was performed to define safe and effective cyclosporine doses and blood levels at various times after transplantation. Patient and graft survival were assessed as efficacy parameters, and serum creatinine and cholesterol levels as safety parameters. The mean daily cyclosporine dose was 12.1 mg/kg/d at 1 month posttransplantation and 5.5 mg/kg/d after 1 year. After 4 years, the mean cyclosporine dose was maintained at 4.0 mg/kg/d. Mean cyclosporine blood levels showed a similar trend. Patient and graft survival after 4 years of cyclosporine maintenance therapy were 72% and 67%, respectively. Both serum creatinine and cholesterol levels were stable over the study period, and neither correlated with cyclosporine does. The cumulative incidence of biopsy-proven acute cellular rejection was 59% for early (<6 months) episodes and 21% for late (≤6 months) episodes. Patient and graft survival did not differ significantly between patients experiencing early or late acute rejection episodes and those who did using univariate analysis. The high patient and graft survival, low rejection rates, and lack of significant renal dysfunction or hypercholesterolemia suggest that the cyclosporine doses and blood levels described are safe end therapeutically effective.

Original languageEnglish (US)
Pages (from-to)34-41
Number of pages8
JournalLiver Transplantation and Surgery
Volume4
Issue number1
StatePublished - 1998

Fingerprint

Graft Survival
Cyclosporine
Liver
Creatinine
Cholesterol
Transplant Recipients
Hypercholesterolemia
Serum
Transplantation
Kidney
Biopsy
Safety
Incidence

ASJC Scopus subject areas

  • Hepatology
  • Surgery

Cite this

Wiesner, R. H., Goldstein, R. M., Donovan, J. P., Miller, C. M., Lake, J. R., & Lucey, M. R. (1998). The impact of cyclosporine dose and level on acute rejection and patient and graft survival in liver transplant recipients. Liver Transplantation and Surgery, 4(1), 34-41.

The impact of cyclosporine dose and level on acute rejection and patient and graft survival in liver transplant recipients. / Wiesner, R. H.; Goldstein, R. M.; Donovan, J. P.; Miller, C. M.; Lake, J. R.; Lucey, M. R.

In: Liver Transplantation and Surgery, Vol. 4, No. 1, 1998, p. 34-41.

Research output: Contribution to journalArticle

Wiesner, RH, Goldstein, RM, Donovan, JP, Miller, CM, Lake, JR & Lucey, MR 1998, 'The impact of cyclosporine dose and level on acute rejection and patient and graft survival in liver transplant recipients', Liver Transplantation and Surgery, vol. 4, no. 1, pp. 34-41.
Wiesner, R. H. ; Goldstein, R. M. ; Donovan, J. P. ; Miller, C. M. ; Lake, J. R. ; Lucey, M. R. / The impact of cyclosporine dose and level on acute rejection and patient and graft survival in liver transplant recipients. In: Liver Transplantation and Surgery. 1998 ; Vol. 4, No. 1. pp. 34-41.
@article{a51f0c39f3a34594a7d97837ca2a7a65,
title = "The impact of cyclosporine dose and level on acute rejection and patient and graft survival in liver transplant recipients",
abstract = "A multicenter, retrospective analysis of 623 liver transplant recipients was performed to define safe and effective cyclosporine doses and blood levels at various times after transplantation. Patient and graft survival were assessed as efficacy parameters, and serum creatinine and cholesterol levels as safety parameters. The mean daily cyclosporine dose was 12.1 mg/kg/d at 1 month posttransplantation and 5.5 mg/kg/d after 1 year. After 4 years, the mean cyclosporine dose was maintained at 4.0 mg/kg/d. Mean cyclosporine blood levels showed a similar trend. Patient and graft survival after 4 years of cyclosporine maintenance therapy were 72{\%} and 67{\%}, respectively. Both serum creatinine and cholesterol levels were stable over the study period, and neither correlated with cyclosporine does. The cumulative incidence of biopsy-proven acute cellular rejection was 59{\%} for early (<6 months) episodes and 21{\%} for late (≤6 months) episodes. Patient and graft survival did not differ significantly between patients experiencing early or late acute rejection episodes and those who did using univariate analysis. The high patient and graft survival, low rejection rates, and lack of significant renal dysfunction or hypercholesterolemia suggest that the cyclosporine doses and blood levels described are safe end therapeutically effective.",
author = "Wiesner, {R. H.} and Goldstein, {R. M.} and Donovan, {J. P.} and Miller, {C. M.} and Lake, {J. R.} and Lucey, {M. R.}",
year = "1998",
language = "English (US)",
volume = "4",
pages = "34--41",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - The impact of cyclosporine dose and level on acute rejection and patient and graft survival in liver transplant recipients

AU - Wiesner, R. H.

AU - Goldstein, R. M.

AU - Donovan, J. P.

AU - Miller, C. M.

AU - Lake, J. R.

AU - Lucey, M. R.

PY - 1998

Y1 - 1998

N2 - A multicenter, retrospective analysis of 623 liver transplant recipients was performed to define safe and effective cyclosporine doses and blood levels at various times after transplantation. Patient and graft survival were assessed as efficacy parameters, and serum creatinine and cholesterol levels as safety parameters. The mean daily cyclosporine dose was 12.1 mg/kg/d at 1 month posttransplantation and 5.5 mg/kg/d after 1 year. After 4 years, the mean cyclosporine dose was maintained at 4.0 mg/kg/d. Mean cyclosporine blood levels showed a similar trend. Patient and graft survival after 4 years of cyclosporine maintenance therapy were 72% and 67%, respectively. Both serum creatinine and cholesterol levels were stable over the study period, and neither correlated with cyclosporine does. The cumulative incidence of biopsy-proven acute cellular rejection was 59% for early (<6 months) episodes and 21% for late (≤6 months) episodes. Patient and graft survival did not differ significantly between patients experiencing early or late acute rejection episodes and those who did using univariate analysis. The high patient and graft survival, low rejection rates, and lack of significant renal dysfunction or hypercholesterolemia suggest that the cyclosporine doses and blood levels described are safe end therapeutically effective.

AB - A multicenter, retrospective analysis of 623 liver transplant recipients was performed to define safe and effective cyclosporine doses and blood levels at various times after transplantation. Patient and graft survival were assessed as efficacy parameters, and serum creatinine and cholesterol levels as safety parameters. The mean daily cyclosporine dose was 12.1 mg/kg/d at 1 month posttransplantation and 5.5 mg/kg/d after 1 year. After 4 years, the mean cyclosporine dose was maintained at 4.0 mg/kg/d. Mean cyclosporine blood levels showed a similar trend. Patient and graft survival after 4 years of cyclosporine maintenance therapy were 72% and 67%, respectively. Both serum creatinine and cholesterol levels were stable over the study period, and neither correlated with cyclosporine does. The cumulative incidence of biopsy-proven acute cellular rejection was 59% for early (<6 months) episodes and 21% for late (≤6 months) episodes. Patient and graft survival did not differ significantly between patients experiencing early or late acute rejection episodes and those who did using univariate analysis. The high patient and graft survival, low rejection rates, and lack of significant renal dysfunction or hypercholesterolemia suggest that the cyclosporine doses and blood levels described are safe end therapeutically effective.

UR - http://www.scopus.com/inward/record.url?scp=0031983330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031983330&partnerID=8YFLogxK

M3 - Article

C2 - 9457965

AN - SCOPUS:0031983330

VL - 4

SP - 34

EP - 41

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 1

ER -